Clinical Trials - February 2, 2017
Sobi and Bioverativ to reveal new data
Swedish Orphan Biovitrum (Sobi) and Bioverativ will present new haemophilia data at the 10th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), taking place in Paris, France, 1-3 February 2017. Nine abstracts from Sobi- and Bioverativ-led studies have been accepted for presentation during EAHAD, reflecting the companies’ commitment to the haemophilia […]
In a new job - January 10, 2017
CEO Geoffrey McDonough to leave Sobi
Swedish Orphan Biovitrum announces that Geoffrey McDonough will leave Sobi on 1 July 2017, and that a search for a new Chief Executive Officer has been initiated to identify his successor. “Geoffrey McDonough has created remarkable value in his term as CEO. Under his leadership Sobi has become a prominent rare disease biotech company with […]
Drug Development Pharma - October 24, 2016
Sobi’s SOBI003 granted orphan designation
Swedish Orphan Biovitrum has been granted orphan designation by the European Commission (EC) for the company’s development product candidate SOBI003, a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome). SOBI003 will be included in the EU Community Register of Orphan Medicinal Products. MPS IIIA or Sanfilippo A syndrome […]
In a new job - September 23, 2016
New Senior Vice President at Sobi
Milan Zdravkovic joins Sobi as Senior Vice President, Head of Research & Development. Milan joins Sobi from Novo Nordisk where he has had an 18 year tenure in the Research and Development organisation responsible for therapeutic areas including diabetes, growth hormone deficiency, obesity and immunology. Milan’s experience spans early stage development to post-approval life-cycle management […]
Pharma Business - June 17, 2016
Sobi’s Orfadin approved in the US
Swedish Orphan Biovitrum announces that the Food and Drug Administration (FDA) has approved a higher strength 20 mg capsule of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney complications and can be […]
Drug Development Pharma - May 13, 2016
Sobi’s Alprolix approved in the EU
Swedish Orphan Biovitrum and Biogen has announced that the European Commission (EC) has approved Alprolix (rFIXFc), their extended half-life therapy, for the treatment of haemophilia B in all 28 European Union (EU) member states and maintained its orphan designation. Alprolix is the only recombinant factor IX Fc Fusion protein therapy for haemophilia B to offer people […]
